Lanean...
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
BACKGROUND: The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal anti...
Gorde:
| Argitaratua izan da: | N Engl J Med |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705202/ https://ncbi.nlm.nih.gov/pubmed/22149875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1113216 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|